In the ten years since its creation, CrossMab technology has grown to become one of the most sophisticated, adaptable, and extensively applied technologies in the field of bispecific antibodies. With 16 of them still undergoing evaluation in ongoing clinical trials, at least 19 bispecific antibodies and fusion proteins based on CrossMab technology created by Roche and other businesses had entered clinical trials as of mid-2021. The most developed of them are the bispecific antibodies directed against CD20/CD3 T cells, glofitamab, which is presently in a pivotal phase 3 study, and Ang-2/VEGF, faricimab, which is presently undergoing regulatory review.